Key statistics
As of last trade, Lyell Immunopharma Inc (LYEL:NSQ) traded at 23.29, 204.44% above the 52 week low of 7.65 set on Jun 02, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 23.78 |
|---|---|
| High | 23.96 |
| Low | 22.54 |
| Bid | 23.00 |
| Offer | 23.38 |
| Previous close | 24.10 |
| Average volume | 120.93k |
|---|---|
| Shares outstanding | 21.24m |
| Free float | 14.08m |
| P/E (TTM) | -- |
| Market cap | 511.98m USD |
| EPS (TTM) | -22.26 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 18:01 GMT.
More ▼
- Lyell Immunopharma Announces Participation in March Investor Conferences
- Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
- Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
- Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
- Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
- Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
- Lyell Immunopharma Announces Participation in September Investor Conferences
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
- Lyell Immunopharma Announces up to $100 Million Equity Private Placement
More ▼
